GLP 1
Survodutide How It Works: Mechanism of Action Explained
Introduction Survodutide is an investigational dual receptor agonist for obesity and MASH liver disease developed jointly by Boehringer Ingelheim and Zealand Pharma. The drug…
Survodutide Latest Research: New Indications, Trials & What’s Coming
Survodutide is among the most-watched investigational drugs for combined obesity and liver disease.
Survodutide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications
Introduction Survodutide is in Phase 3 development with two primary indications under investigation: obesity (SYNCHRONIZE-1 and SYNCHRONIZE-2 trials) and MASH liver disease (LIVERAGE program)….
Survodutide Drug Interactions: What You Can and Can’t Take with It
Survodutide isn’t on the market yet, so no FDA-issued interaction label exists.
Survodutide Dosing Guide: Schedule, Titration & What to Expect Each Week
Survodutide dosing is set by the Phase 2 and ongoing Phase 3 protocols from Boehringer Ingelheim and Zealand Pharma.
Survodutide Cost Breakdown: Brand, Compounded, Insurance & Savings Options
Survodutide is still in Phase 3 development, so no commercial pricing exists yet.
Supplements to Take (and Avoid) on GLP-1 Medications
Rapid weight loss creates real nutrient gaps.
Strength Training on GLP-1: The #1 Way to Prevent Muscle Loss
When the STEP 1 trial (Wilding et al.
Stockpiling GLP-1: Why It’s Counterproductive
When supply gets tight, the natural instinct is to grab extra. Patients who can fill three months at once try to fill six.
